The American Society of Clinical Oncology Annual Meeting is one of the premier scientific conferences in the world for research and treatment of cancer. It is typically attended by more than 30,000 clinicians, researchers, industry executives, and patient advocates. In 2020, the meeting is being conducted in a virtual format due to the ongoing COVID-19 pandemic.
The reported progression-free survival (PFS) figure of 8.4 months compares favourably with the PFS of 5.3 months that is associated with temozolomide in this patient population. In April 2020, Kazia reported an interim analysis showing a PFS of 8.5 months in the overall study population (n=30). This poster only reports the first stage of the study (n=9), and the figure in this part of the study was 8.4 months.
imo
Patient pool of 9 and 30
Premier world conference
30000 clinicians and share price at 50% off April 2018 prices and lower than pre gdc0084 purchase in 2016
dyor
The American Society of Clinical Oncology Annual Meeting is one...
-
- There are more pages in this discussion • 1,511 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)